New TRIM5α-based treatments can knock out HIV in humans: Research

NewsGuard 100/100 Score

Using a $225,000 microscope, researchers have identified the key components of a protein called TRIM5α that destroys HIV in rhesus monkeys.

The finding could lead to new TRIM5α-based treatments that would knock out HIV in humans, said senior researcher Edward M. Campbell, PhD, of Loyola University Health System.

Campbell and colleagues report their findings in an article featured on the cover of the Sept. 15, 2010 issue of the journal Virology, now available online.

In 2004, other researchers reported that TRIM5α protects rhesus monkeys from HIV. The TRIM5α protein first latches on to a HIV virus, then other TRIM5α proteins gang up and destroy the virus.

Humans also have TRIM5α, but while the human version of TRIM5α protects against some viruses, it does not protect against HIV.

Researchers hope to turn TRIM5α into an effective therapeutic agent. But first they need to identify the components in TRIM5α that enable the protein to destroy viruses. "Scientists have been trying to develop antiviral therapies for only about 75 years," Campbell said. "Evolution has been playing this game for millions of years, and it has identified a point of intervention that we still know very little about."

TRIM5α consists of nearly 500 amino acid subunits. Loyola researchers have identified six 6 individual amino acids, located in a previously little-studied region of the TRIM5α protein, that are critical in the ability of the protein to inhibit viral infection. When these amino acids were altered in human cells, TRIM5α lost its ability to block HIV-1 infection. (The research was done on cell cultures; no rhesus monkeys were used in the study.)

By continuing to narrow their search, researchers hope to identify an amino acid, or combination of amino acids, that enable TRIM5α to destroy HIV. Once these critical amino acids are identified, it might be possible to genetically engineer TRIM5α to make it more effective in humans. Moreover, a better understanding of the underlying mechanism of action might enable the development of drugs that mimic TRIM5α action, Campbell said.

In their research, scientists used Loyola's wide-field "deconvolution" microscope to observe how the amino acids they identified altered the behavior of TRIM5α. They attached fluorescent proteins to TRIM5α to, in effect, make it glow. In current studies, researchers are fluorescently labeling individual HIV viruses and measuring the microscopic interactions between HIV and TRIM5α.

"The motto of our lab is one of Yogi Berra's sayings -- 'You can see a lot just by looking,'" Campbell said.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Common HIV drugs linked to reduced Alzheimer's disease risk